Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
C&EN13h
Kennedy orders FDA to review food ingredient loophole
US Health and Human Services secretary Robert F. Kennedy Jr. directs the Food and Drug Administration to explore revamping ...
CNN16d
FDA delays when a final rule on what foods can be labeled as ‘healthy’ goes into effect
The US Food and Drug Administration’s new standards for foods before they can be labeled as “healthy” on their packaging will go into effect about two months later than planned, according to ...
GEN - Genetic Engineering and Biotechnology News3d
StockWatch: Trump’s FDA Nominee Eyes Rare Disease-Specific Review Pathways
President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...
Clinical Trials Arena on MSN6d
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
Hosted on MSN29d
Biohaven stock rises following FDA review and Deutsche Bank's buy rating
Deutsche Bank analyst David Hoang initiated coverage on Biohaven with a Buy rating and a price target ... stage clinical assets," Hoang stated. The FDA's decision to grant Priority Review to ...
Benzinga.com9d
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
FDA approved Tevimbra plus chemo for first-line treatment of PD-L1-positive metastatic ESCC, showing a 34% reduced risk of death in trials. In a Phase 3 study, Tevimbra plus chemo improved median ...